Loading
Adding pembrolizumab to platinum-pemetrexed chemotherapy lengthened survival in untreated pleural mesothelioma by about a year in non-epithelioid tumours and by a smaller margin overall, giving a chemo-immunotherapy option alongside nivolumab-ipilimumab.
Phase 3 open-label trial of 440 patients with unresectable advanced pleural mesothelioma in Canada, Italy and France randomised to pembrolizumab plus platinum-pemetrexed or chemotherapy alone.
Median overall survival was 17.3 versus 16.1 months (hazard ratio 0.79), with three-year survival 25 versus 17 percent and a larger effect in non-epithelioid disease; grade 3 to 4 adverse events were more frequent with pembrolizumab.
Pembrolizumab with chemotherapy is approved and offered first line, particularly in epithelioid disease where dual immunotherapy showed little benefit over chemotherapy.
Shares Pleural mesothelioma, The Lancet.
Shares IND.227 / KEYNOTE-483, Pembrolizumab.
Shares The Lancet, Pembrolizumab.
Shares The Lancet, Pembrolizumab.
Shares The Lancet, Pembrolizumab.
Shares The Lancet, Pembrolizumab.
Shares The Lancet, Pembrolizumab.
Shares Pleural mesothelioma, Pembrolizumab.